Search Browse Earnings

Pulmatrix, Inc.

Nasdaq:PULM

Pharmaceutical Preparations·FRAMINGHAM, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Pulmatrix, Inc. — SlamSEC

Revenue

$7.8M

+7.0% YoY

FY 2025

Adj. EBITDA

-$9.6M

-123.0% margin

FY 2025

Net Income

-$9.6M

-122.5% margin

FY 2025

EPS (Diluted)

-$2.62

FY 2025

Stock Price

$2.23

+8.8%

2026-03-10

52W Range

$1.63 – $9.37

P/E Ratio

-0.9x

Market Cap

$8.1M

Cash

$9.5M

FY 2025

Total Debt

$3.2M

FY 2017

Net Cash

$6.3M

FY 2017

Enterprise Value

$1.8M

Debt / EBITDA

0.7x

FY 2025

EV / EBITDA

-0.2x

Employees

—

CEO

Raad Teofilo David